Klotho Neurosciences Reports Increased Net Loss of $2.23 Million in Q1 2025

Klotho Neurosciences, Inc. reported a significant increase in its net loss for the first quarter of 2025, amounting to $2.23 million, compared to a net loss of $672,044 in the same period of the previous year. The company's operating expenses surged to $1.59 million, up from $672,045, primarily driven by higher professional fees, general administrative costs, and share-based compensation. The net loss per share for the quarter was $0.08, compared to $0.04 in the prior year.

The company's financial position showed a notable increase in total assets, which rose to approximately $2.99 million as of March 31, 2025, compared to $2.46 million at the end of 2024. This increase was largely attributed to a rise in cash reserves, which grew to $565,869 from $63,741, reflecting successful financing activities that generated $2.06 million in cash during the quarter. However, total liabilities also increased significantly to $2.35 million, up from $1.27 million, primarily due to an increase in notes payable.

In terms of strategic developments, Klotho Neurosciences completed a business combination with Redwoods Acquisition Corp. in June 2024, which was treated as a reverse acquisition for accounting purposes. The company has also been active in expanding its product offerings, having acquired licenses for various drug platforms, including a generic drug portfolio and a biosimilar biologics platform. Additionally, on March 26, 2025, Klotho entered into a Share Exchange Agreement to acquire SB Security Holdings, LLC, which is expected to enhance its operational capabilities.

Operationally, Klotho remains in a pre-revenue state, with no revenue generated during the reported quarter. The company is focused on developing essential medicines for chronic diseases, including cancer and neurodegenerative disorders. As of March 31, 2025, Klotho had 32,494,389 shares of common stock outstanding, reflecting its ongoing efforts to raise capital through equity financing. The company is classified as a smaller reporting company and an emerging growth company, which allows it to take advantage of certain regulatory exemptions.

Looking ahead, Klotho Neurosciences faces challenges related to its liquidity and ongoing operational costs. The company reported a net working capital deficit of approximately $1.65 million and has indicated that it requires additional funding to continue its business operations. Without securing further capital, there is substantial doubt about the company's ability to continue as a going concern over the next twelve months. The management is actively seeking additional funding through equity and debt securities to support its development plans and operational needs.